Related Experiment Videos
The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein
J Keleti1, M M Quezado, M M Abaza
1Pediatric Tumor Biology-Ultrastructural Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
MDM2 gene overexpression has been implicated in the pathogenesis of human neoplasia via inhibition of the p53 tumor-suppressor function. To investigate the potential involvement of the MDM2 oncogene in the pathogenesis of childhood rhabdomyosarcoma (RMS) we studied MDM2 abnormalities in six RMS cell lines in correlation with the p53 status. Three showed overexpression of MDM2 mRNA and protein, one with concomitant MDM2 gene amplification. All three lacked p53 mutation and expressed low levels of p53 mRNA but exhibited elevated p53 proteins. Double immunostaining revealed that the overexpressed MDM2 and p53 proteins were co-localized to the same cell nuclei. Furthermore, the two proteins were physically associated, as shown by co-immunoprecipitation and Western blot analysis. The half-life of the p53 protein was prolonged in the MDM2-expressing RMS cells. The extended half-life wildtype p53 protein and its complex formation with the elevated MDM2 suggest that the underlying mechanism for p53 protein accumulation in these cell lines is p53 stabilization by an overabundant MDM2 protein. The overexpressed MDM2 protein had a short half-life. The three remaining RMS cell lines exhibited low MDM2 mRNA and protein levels and carried p53 mutations. This study suggest that MDM2 overexpression represents an alternative mechanism for p53 inactivation in a subset of childhood RMS without p53 mutations. The results further indicate that the elevated MDM2 protein is responsible for wildtype p53 protein accumulation via stabilization.
Insights
MDM2 gene overexpression inhibits p53 function in some childhood rhabdomyosarcoma (RMS) cases. This study found elevated MDM2 protein stabilizes wild-type p53, leading to its accumulation in RMS cells lacking p53 mutations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MDM2 gene overexpression is linked to human neoplasia by inhibiting p53 tumor suppressor function.
- Understanding MDM2's role in childhood rhabdomyosarcoma (RMS) pathogenesis is crucial for targeted therapies.
Purpose of the Study:
- To investigate MDM2 gene abnormalities in RMS cell lines.
- To correlate MDM2 status with p53 mutations and protein levels.
- To elucidate the mechanism of p53 regulation by MDM2 in RMS.
Main Methods:
- Studied six RMS cell lines for MDM2 abnormalities (gene amplification, mRNA, and protein levels).
- Assessed p53 status (mutation, mRNA, and protein levels).
- Utilized double immunostaining, co-immunoprecipitation, and Western blot analysis to examine MDM2-p53 interactions and protein half-lives.
Main Results:
- Three RMS cell lines showed MDM2 overexpression (one with gene amplification), lacking p53 mutations but exhibiting elevated p53 protein.
- Overexpressed MDM2 and p53 proteins were co-localized and physically associated in RMS cell nuclei.
- MDM2 overexpression led to p53 protein stabilization and accumulation, prolonging its half-life in the absence of p53 mutations.
- The remaining three RMS cell lines had low MDM2 levels and carried p53 mutations.
Conclusions:
- MDM2 overexpression is an alternative mechanism for p53 inactivation in a subset of childhood RMS lacking p53 mutations.
- Elevated MDM2 protein stabilizes wild-type p53, causing its accumulation.
- This finding highlights MDM2 as a potential therapeutic target in specific RMS subtypes.